Daiichi Sankyo

This study tests a new drug, DS-8201a, against standard treatments for people with a specific type of advanced breast cancer called HER2-low. The cancer has spread or cannot be removed by surgery, and prior treatments have stopped working. The goal is to see if the new drug can s…

This phase 3 study tests whether a new drug, DS-8201a, works better than the current standard T-DM1 for people with advanced HER2-positive breast cancer that has spread or cannot be removed. About 524 adults who have already tried trastuzumab and taxane will receive one of the tw…

This study tests an experimental drug called quizartinib, given with chemotherapy, for children and young adults (ages 1 month to 21 years) whose acute myeloid leukemia (AML) has come back or not responded to treatment. The goal is to see if the combination can safely help achiev…

This study tests a new drug, trastuzumab deruxtecan, against a standard combination therapy in people with advanced HER2-positive stomach or gastro-esophageal junction cancer that has worsened after initial treatment. About 490 adults will be randomly assigned to receive either t…

This study tests an experimental drug called patritumab deruxtecan in people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to other treatments. The main goal is to see if the drug can shrink tumors. About 277 participants wi…

This early-stage study tests an experimental drug called HER3-DXd in people with advanced non-small cell lung cancer (NSCLC) that has stopped responding to other treatments. The goal is to check the drug's safety and see if it can shrink tumors. The study includes patients with d…

This study compares a new drug, DS-1062a, to a standard chemotherapy (docetaxel) in about 605 adults with advanced or metastatic non-small cell lung cancer that has already been treated. The goal is to see if DS-1062a can better delay cancer growth and extend survival. Participan…

This early-stage study tests a new drug, DS-1001b, in 47 adults with a specific type of brain tumor (glioma) that has a certain genetic change (IDH1 mutation) and has come back after standard treatments. The main goal is to check the drug's safety and how the body processes it. R…

This early-stage study tests a combination of two drugs—trastuzumab deruxtecan and pembrolizumab—in people with advanced breast or non-small cell lung cancer that has spread. The goal is to find the best dose and see how well the combo shrinks tumors. About 115 adults with HER2-p…

This study tests whether a new drug combination (datopotamab deruxtecan plus pembrolizumab) works better than standard chemo plus immunotherapy for people with advanced non-small cell lung cancer who haven't had treatment yet. About 1,170 adults with a specific tumor marker (PD-L…

This early-stage study tests a new drug combination (datopotamab deruxtecan plus pembrolizumab, with or without chemo) in 145 people with advanced or metastatic non-small cell lung cancer. The goal is to see if the treatment is safe and can shrink tumors or slow disease progressi…

This study tests a newer targeted therapy (trastuzumab deruxtecan) against an older one (trastuzumab emtansine) in 1,600 people with high-risk HER2-positive breast cancer who still have cancer after initial treatment. The goal is to see if the newer drug helps prevent cancer from…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) in people with advanced small cell lung cancer that has spread and has been treated before. The goal is to see if the drug can shrink tumors and find the best dose. About 187 adults will take part in this Phase 2 tr…

This early-phase study tests a new drug called DS-1055a in about 40 adults with advanced solid tumors (like head and neck, stomach, or lung cancer) that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. Participants re…

This study tests a drug called valemetostat tosylate in people with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or not improved after other treatments. About 155 adults will take the drug and be monitored for tumor shrinkage and side effects. The go…

This study tracks 721 Chinese adults with diabetic peripheral neuropathic pain to see how safe and effective mirogabalin is in everyday medical practice. Participants must have moderate to severe pain and have not taken mirogabalin before. The main focus is on side effects like d…

This study is observing over 2,500 adults with high cholesterol or mixed dyslipidemia who are taking bempedoic acid (alone or with ezetimibe) as part of their normal care. The goal is to see how safe and effective the drug is in real-world settings, especially in Asian and Latin …

This study looks at how doctors treat advanced or metastatic triple-negative breast cancer in Canada, the UK, France, and Spain. Researchers will collect information from medical records of about 760 patients to understand which tests and treatments are used and how well they wor…